Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

Completed · Phase 4

Conditions studied: Hypertension, Left Ventricular Diastolic Dysfunction

In brief

To investigate whether treatment with Nebivolol in subjects with high blood pressure and abnormal filling of left ventricle (LVDD) improves exercise time by improving Left Ventricular deformation and filling.

Key facts

Study ID

NCT01961323

Run by

Icahn School of Medicine at Mount Sinai

People needed

70

Starts

2012-03-01

Expected to finish

2016-03-01

Last updated by the study team

2017-11-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of mild (140-160 / 90-100) to moderate (160-200 / 100-120) hypertension
• LV diastolic dysfunction (>/= Grade1)
• LV ejection fraction >50%
• Indexed left atrial volume >/= 28 mL/m\^2
• In sinus rhythm at the time of enrollment
• Willingness to return for the 6-month follow up investigations

You may not qualify if…

• Presence or history of any of the following at baseline:
• History of mitral valve disease of greater than mild severity or prosthetic mitral valve, congenital heart disease or permanent pacemaker
• Calculated creatinine clearance <50 mL/min
• Terminal Illness with expected Survival of <1 year
• Previous Heart Transplant
• Individuals who are institutionalized
• Systolic BP>180 mm Hg or diastolic BP > 120 mm Hg
• Medical treatment for elevated BP with:
• Calcium channel blocker (e.g. verapamil, nifedipine);
• Alpha blocker (e.g. prazosin);
• Alpha agonist (e.g. α-methyldopa, hydralazine, clonidine)
• Patient unwilling or unable to provide informed consent for study participation
• Pregnancy (current, or anticipated within the study period)
• Secondary Hypertension
• Previous echo contrast allergy
• Poor echocardiography window
• Previous stroke, known carotid stenosis
• Contraindication for beta-blocker therapy (sinus bradycardia <50 beats/min);
• 2nd or 3rd degree AV conduction block
• Overt congestive cardiac failure (NYHA Class III-IV)
• Known bronchospastic disease
• Known hepatic dysfunction (SGOT/PT > twice above normal levels)

Where it is running

• Icahn School of Medicine at Mount Sinai — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.